# Yi Hu

**Type:** Researchers  
**Canonical URL:** https://scholariq.org/researchers/yi-hu-2/

## Facts

| Field | Value |
| --- | --- |
| Citations | 16,178 |
| Field | Cancer Immunotherapy and Biomarkers |
| h-index | 47 |
| i10-index | 208 |
| Last Known Institution | Chinese PLA General Hospital |
| OpenAlex ID | https://openalex.org/A5042174429 |
| ORCID iD | https://orcid.org/0000-0001-9319-5692 |
| Works | 532 |

## Researcher papers

- [Durvalumab plus platinum–etoposide versus platinum–etoposide in first-line treatment of extensive-stage small-cell lung cancer (CASPIAN): a randomised, controlled, open-label, phase 3 trial](https://scholariq.org/papers/durvalumab-plus-platinum-etoposide-versus-platinum-etoposide-in-first-line/)
- [Camrelizumab versus investigator's choice of chemotherapy as second-line therapy for advanced or metastatic oesophageal squamous cell carcinoma (ESCORT): a multicentre, randomised, open-label, phase 3 study](https://scholariq.org/papers/camrelizumab-versus-investigator-s-choice-of-chemotherapy-as-second-line-therapy/)
- [Camrelizumab plus carboplatin and pemetrexed versus chemotherapy alone in chemotherapy-naive patients with advanced non-squamous non-small-cell lung cancer (CameL): a randomised, open-label, multicentre, phase 3 trial](https://scholariq.org/papers/camrelizumab-plus-carboplatin-and-pemetrexed-versus-chemotherapy-alone-in/)
- [γδ T cells: origin and fate, subsets, diseases and immunotherapy](https://scholariq.org/papers/t-cells-origin-and-fate-subsets-diseases-and-immunotherapy/)
- [Efficacy, safety, and biomarker analysis of ensartinib in crizotinib-resistant, ALK-positive non-small-cell lung cancer: a multicentre, phase 2 trial](https://scholariq.org/papers/efficacy-safety-and-biomarker-analysis-of-ensartinib-in-crizotinib-resistant-alk/)

## Researcher topics

- [Cancer Immunotherapy and Biomarkers](https://scholariq.org/topics/cancer-immunotherapy-and-biomarkers/)
- [Lung Cancer Treatments and Mutations](https://scholariq.org/topics/lung-cancer-treatments-and-mutations/)
- [Lung Cancer Research Studies](https://scholariq.org/topics/lung-cancer-research-studies/)
- [Lung Cancer Diagnosis and Treatment](https://scholariq.org/topics/lung-cancer-diagnosis-and-treatment/)
- [Cancer Genomics and Diagnostics](https://scholariq.org/topics/cancer-genomics-and-diagnostics/)

## Researcher university

- [Chinese PLA General Hospital](https://scholariq.org/institutions/chinese-pla-general-hospital/)

---
Source: ScholarIQ — public research metadata, principally OpenAlex. See https://scholariq.org/sources/ for provenance and https://scholariq.org/methodology/ for what these figures mean.